Phase III study of Edarbyclor (Takeda) shows positive results for Hypertension

Results of a 12-week, head-to-head, Phase III study found systolic blood pressure (SBP) reductions of Edarbyclor (azilsartan medoxomil and chlorthalidone), from Takeda, were statistically superior to those of the fixed-dose combination of olmesartan medoxomil-hydrochlorothiazide in patients with Hypertension. Results after 12 weeks of treatment showed that the fixed-dose combination of azilsartan medoxomil and chlorthalidone 40/25 mg reduced clinic SBP by 42.5 mm Hg from baseline. The reductions were statistically significantly greater than that of the fixed-dose combination of olmesartan medoxomil-hydrochlorothiazide 40/25 mg (37.1 mm Hg). Similar results were observed across patient subgroups, including age, gender or race. Edarbyclor was approved by the FDA in December 2011 for the treatment of hypertension to lower blood pressure in adults. Results are published online in the American Heart Association journal Hypertension.